Iterum Therapeutics faces a mixed reception for its therapy for uncomplicated urinary tract infections (UTIs) as experts ...

The EMA CHMP has recommended granting approval for AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis ...

Takeda has secured the Japanese MHLW approval for its FRUZAQLA to treat unresectable advanced or recurrent colorectal cancer ...

The EC has granted marketing authorisation to LEO Pharma’s Anzupgo cream for treating adults with moderate to severe chronic ...

UCB has received US FDA approval for BIMZELX (bimekizumab-bkzx) to treat adults with three inflammatory conditions.

According to GlobalData’s company profile on Sword Health, Treatment progress monitoring was a key innovation area identified from patents. Sword Health's grant share as of July 2024 was 23%. Grant ...

According to GlobalData’s company profile on Praxis Precision Medicines, Peptide pharmacophores was a key innovation area identified from patents. Praxis Precision Medicines's grant share as of July ...

The granted patent US12049488B2 describes a modular synthetic receptor designed for specific ligand binding and functional activity initiation. The receptor consists of three main components: an ...

According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of July ...

The granted patent US12060390B2 outlines a novel adeno-associated virus (AAV) vector characterized by its specific capsid protein, which includes the amino acid sequence designated as SEQ ID NO: 2110.

The patent US12016952B2 outlines a method for preparing a monodisperse oligo(ethylene glycol) reagent composition through a series of chemical reactions. The process ...

According to GlobalData’s company profile on Ardelyx, Peptide pharmacophores was a key innovation area identified from patents. Ardelyx's grant share as of July 2024 was 39%. Grant share is based on ...